Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fluoxetine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 12/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | HTR2C | P28335 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | APEX1 | P27695 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | GPR183 | P32249 | 1/20 | 1.00 |
| ▸ | APLNR | P35414 | 1/20 | 1.00 |
| ▸ | CX3CR1 | P49238 | 1/20 | 1.00 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 1.00 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluoxetine SCHEMBL33384 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2MEN1LMNAKMT2A | |
| Fluoxetine SCHEMBL7081402 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2MEN1LMNAKMT2A | |
| Fluoxetine SCHEMBL56333 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2MEN1LMNAKMT2A | |
| R-Fluoxetine SCHEMBL3905325 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2MEN1LMNAKMT2A | |
| Fluoxetine SCHEMBL8911991 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2MEN1LMNAKMT2A | |
| Fluoxetine SCHEMBL33947 | 0.99 | SLC6A4 (1.00) | SLC6A4SLC6A2MEN1LMNAKMT2A | |
| Fluoxetine SCHEMBL570572 | 0.99 | SLC6A4 (1.00) | SLC6A4SLC6A2MEN1LMNAKMT2A | |
| Fluoxetine SCHEMBL8467346 | 0.99 | SLC6A4 (1.00) | SLC6A4SLC6A2MEN1LMNAKMT2A | |
| Fluoxetine SCHEMBL8353 | 0.99 | SLC6A4 (1.00) | SLC6A4SLC6A2MEN1LMNAKMT2A | |
| R-Fluoxetine SCHEMBL1200433 | 0.99 | SLC6A4 (1.00) | SLC6A4SLC6A2MEN1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102175778-A | Method for synchronously measuring blood drug concentrations of multiple antidepressants | HANGZHOU GUGE SCIENCE AND TECHNOLOGY CO LTD | 2011-09-07 | — | — | CN | claimed |
| US-11690553-B2 | Multimodal brain sensing lead | NEUROPACE, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-11026617-B2 | Multimodal brain sensing lead | NEUROPACE, INC. (US) | 2021-06-08 | — | — | US | disclosed |
| US-20190298211-A1 | MULTIMODAL BRAIN SENSING LEAD | NEUROPACE INC. | 2019-10-03 | — | — | US | disclosed |
| US-10390721-B2 | Multimodal brain sensing lead | NEUROPACE, INC. (US) | 2019-08-27 | — | — | US | disclosed |
| US-10123717-B2 | Multimodal brain sensing lead | NEUROPACE, INC. (US) | 2018-11-13 | — | — | US | disclosed |
| US-20180117175-A1 | TEMPLATED NANOCONJUGATES | NORTHWESTERN UNIVERSITY | 2018-05-03 | — | — | US | disclosed |
| EP-2494075-B1 | TEMPLATED NANOCONJUGATES | UNIV NORTHWESTERN (US) | 2018-04-04 | — | — | EP | disclosed |
| US-9757475-B2 | Templated nanoconjugates | NORTHWESTERN UNIVERSITY (US) | 2017-09-12 | — | — | US | disclosed |
| US-20170238832-A1 | MULTIMODAL BRAIN SENSING LEAD | MIDCAP FUNDING IV TRUST | 2017-08-24 | — | — | US | disclosed |
| US-6746678-B1 | Method of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with medicaments | SECANT PHARMA, LLC | 2004-06-08 | — | — | US | disclosed |
| EP-0707446-A4 | PHARMACEUTICAL COMPOSITIONS AND USE THEREOF FOR TREATMENT OF NEUROLOGICAL DISEASES AND ETIOLOGICALLY RELATED SYMPTOMOLOGY | SHAPIRO HOWARD K (US) | 2001-01-10 | — | — | EP | disclosed |
| US-6060642-A | TRANSGENIC MICE MODELS FOR GENE FUNCTION, WHEREIN THE TRANSGENIC MICE ARE CHARACTERIZED BY HAVING ALTERED SEROTONIN 5-HT6 RECEPTOR GENE FUNCTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-05-09 | — | — | US | disclosed |
| CN-1250373-A | Composition and method for suppelmenting testosterone in women with symptoms of testosterone deficiency | THERATECH INC (US) | 2000-04-12 | — | — | CN | disclosed |
| EP-0759750-A4 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1998-05-27 | — | — | EP | disclosed |
| US-5668117-A | NERVOUS SYSTEM DISORDERS USING AROMATIC ACID COMPOUNDS | SECANT PHARMA, LLC | 1997-09-16 | — | — | US | disclosed |
| EP-0759750-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO, Howard, K. (US) | 1997-03-05 | — | — | EP | disclosed |
| EP-0707446-A1 | PHARMACEUTICAL COMPOSITIONS AND USE THEREOF FOR TREATMENT OF NEUROLOGICAL DISEASES AND ETIOLOGICALLY RELATED SYMPTOMOLOGY | SHAPIRO, Howard, K. (US) | 1996-04-24 | — | — | EP | disclosed |
| WO-1995031194-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1995-11-23 | — | — | WO | disclosed |
| WO-1995001096-A1 | PHARMACEUTICAL COMPOSITIONS AND USE THEREOF FOR TREATMENT OF NEUROLOGICAL DISEASES AND ETIOLOGICALLY RELATED SYMPTOMOLOGY | SHAPIRO HOWARD K (US) | 1995-01-12 | — | — | WO | disclosed |